Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 19, Issue 4, pp. 1052-1058
PubMed
Published By
Print ISSN
Online ISSN
History
- Received October 24, 2019
- Revision received January 7, 2020
- Accepted January 28, 2020
- Published first February 5, 2020.
Article Versions
- Previous version (February 5, 2020 - 07:17).
- You are viewing the most recent version of this article.
Copyright & Usage
©2020 American Association for Cancer Research.
Author Information
- Lidia Nazarova1,#,
- Hanine Rafidi1,#,
- Danielle Mandikian1,
- Gregory Z. Ferl1,2,
- James T. Koerber3,
- Christopher W. Davies3,
- Sheila Ulufatu4,
- Jason Ho4,
- Jeffrey Lau5,
- Shang-Fan Yu5,
- James Ernst6,
- Jack D. Sadowsky6, and
- C. Andrew Boswell1,*
- 1Preclinical and Translational Pharmacokinetics, Genentech Research and Early Development, South San Francisco, California.
- 2Biomedical Imaging, Genentech Research and Early Development, South San Francisco, California.
- 3Antibody Engineering, Genentech Research and Early Development, South San Francisco, California.
- 4In Vivo Studies, Genentech Research and Early Development, South San Francisco, California.
- 5Translational Oncology, Genentech Research and Early Development, South San Francisco, California.
- 6Protein Chemistry, Genentech Research and Early Development, South San Francisco, California.
- ↵*Corresponding Author:
C. Andrew Boswell, Genentech Inc., 1 DNA Way, MS 463A, South San Francisco, CA 94080. Phone: 650-467-4603; Fax: 650-742-5234; E-mail: boswell.andy{at}gene.com
↵#L. Nazarova and H. Rafidi contributed equally to this article.
April 2020
Volume 19, Issue 4
Volume 19, Issue 4
Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-length Antibodies
Jump to section
Advertisement